Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) today reports its consolidated financial
results for the three-month period ended May 31, 2010, appoints IR
firm and updates on options and warrants.
Three-month Ended May 31, 2010 Financial
Results
Consolidated Results
- Revenue increased by 45% to $4,162,000 for the three-month
period ended May 31, 2010, up from $2,878,000 achieved during the
corresponding period ended May 31, 2009.
- Consolidated EBITDA for the three-month period ended May 31,
2010 amounted to $676,000, compared to negative $284,000 obtained
during the corresponding period ended May 31, 2009.
- Net earnings increased by $1,883,000 and reached a net income
of $476,000, or $0.01 per share for the three-month period ended
May 31, 2010, compared to a net loss of $1,407,000, or $0.04 per
share, for the corresponding period ended May 31, 2009.
Nutraceutical Business Results
- Nutraceutical revenue increased by 45% to $4,145,000, for the
three-month period ended May 31, 2010, up from $2,859,000 achieved
during the corresponding period ended May 31, 2009.
- EBITDA from nutraceutical business for the three-month period
ended May 31, 2010 was $1,084,000, compared to $36,000 obtained
during the corresponding period ended February 29, 2009.
- Earnings from nutraceutical business improved by $2,489,000 and
reached a net income of $886,000 for the three-month period ended
May 31, 2010, compared to a net loss of $1,603,000, for the
corresponding period ended May 31, 2009.
"We are extremely pleased with the revenue and profitability
level reached during this first quarter, especially with net income
from the nutraceutical segment, which amounts to 21% of our
sales. We now see the impact of the investment we made last
year in Neptune's manufacturing plant, which has translated into
increased and improved production performance and led to these
results," stated Xavier Harland, Director, Finance.
"This strong growth in revenue along with the consolidated net
income generated during the first quarter represents an achievement
and reinforces Neptune's business strategy of generating cash flow
in order to finance research & development programs, which
should contribute to building Neptune's fundamental value," stated
André Godin, Vice-President, Finance & Administration.
Neptune Appoints The Howard Group ("HG") as Investor
Relation ("IR") Firm for Canada
Neptune has entered into an IR agreement with HG to develop and
implement a capital markets program for Canada (the
"Agreement"). The Agreement is subject to TSX-Venture
approval. Traditional and new online initiatives will be
directed at the investment community and investing public to
increase the following and participation of the market in
Neptune.
Since 1988, HG has provided comprehensive investor and capital
markets programs, business development solutions, strategic
planning and financing services to public companies. HG is
associated with the Insight Limited Partnerships I & II, which
invest in micro and small cap companies. Insight LP II currently
owns 100,000 shares of Neptune.
The term of the IR Agreement is for an initial period of 12
months. In addition to a fee of $6,000 per month, HG has been
granted options to purchase an aggregate total of 50,000 common
shares of Neptune at a price of $1.50 per share. The options
will vest in equal amounts at the rate of 25% per quarter and have
a three-year term expiring on July 31, 2013.
In addition, HG will receive 150,000 warrants in Acasti Pharma
Inc., with an exercise price of $0.50 per common share, expiring
December 31, 2010.
Update on Warrants, Call-Option and Incentive Stock
Options
From the beginning of the first quarter to date, 1,098,000
Debenture Warrants, 1,086,400 Debenture Call-Options and 870,000
incentive stock options have been exercised, representing total
proceeds of $1,861,600. Pursuant to theses exercises,
management and employees have acquired 978,000 shares of
Neptune and 106,400 shares of Acasti in less than four months.
As of July 13, 2010, the Board of Directors of Neptune has
decided, after nearly 2 years without a general incentive option
grant to employees and management, to grant a total of 790,000
incentive stock options of Neptune, 760,000 rights on Acasti series
4 warrants held by Neptune and 760,000 rights on Neurobiopharm
series 4 warrants held by Neptune to insiders and
employees. Neptune incentive stock options have an exercise
price of $1.50 and a 3 year maturity. Rights on Acasti series
4 warrants and rights on Neurobiopharm series 4 warrants have an
aggregate exercise price of $0.50 and $0.25 and maturities of
October 9, 2013 and December 24, 2013, respectively, and are
subject to shareholder approval. Insiders have been granted a
total of 450,000 Neptune incentive stock options, 550,000 Rights on
Acasti series 4 warrants and 550,000 rights on Neurobiopharm series
4 warrants.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P., Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024